{"transactions":[{"id":708156,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-07-17T01:58:22.000Z","date":"2026-07-16","kind":"purchase","planned":false,"acquired":true,"shares":2,"price":1.55,"value":3.1,"ownership":{"direct":false,"nature":"By Vivo Opportunity Cayman Fund, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":75019,"source":{"system":"sec-edgar","filing":"0001213900-26-078891","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026078891/ownership.xml","form_type":"4"}},{"id":708155,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-07-17T01:58:22.000Z","date":"2026-07-16","kind":"purchase","planned":false,"acquired":true,"shares":19,"price":1.55,"value":29.45,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":743057,"source":{"system":"sec-edgar","filing":"0001213900-26-078891","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026078891/ownership.xml","form_type":"4"}},{"id":708154,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-07-17T01:58:22.000Z","date":"2026-07-15","kind":"purchase","planned":false,"acquired":true,"shares":1389,"price":1.55,"value":2152.95,"ownership":{"direct":false,"nature":"By Vivo Opportunity Cayman Fund, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":75017,"source":{"system":"sec-edgar","filing":"0001213900-26-078891","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026078891/ownership.xml","form_type":"4"}},{"id":708153,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-07-17T01:58:22.000Z","date":"2026-07-15","kind":"purchase","planned":false,"acquired":true,"shares":13761,"price":1.55,"value":21329.55,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":743038,"source":{"system":"sec-edgar","filing":"0001213900-26-078891","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026078891/ownership.xml","form_type":"4"}},{"id":708152,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-07-17T01:58:22.000Z","date":"2026-07-14","kind":"purchase","planned":false,"acquired":true,"shares":493,"price":1.55,"value":764.15,"ownership":{"direct":false,"nature":"By Vivo Opportunity Cayman Fund, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":73628,"source":{"system":"sec-edgar","filing":"0001213900-26-078891","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026078891/ownership.xml","form_type":"4"}},{"id":708151,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-07-17T01:58:22.000Z","date":"2026-07-14","kind":"purchase","planned":false,"acquired":true,"shares":4882,"price":1.55,"value":7567.1,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":729277,"source":{"system":"sec-edgar","filing":"0001213900-26-078891","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026078891/ownership.xml","form_type":"4"}},{"id":718357,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-07-02T23:02:11.000Z","date":"2026-07-02","kind":"purchase","planned":false,"acquired":true,"shares":147,"price":1.55,"value":227.85,"ownership":{"direct":false,"nature":"By Vivo Opportunity Cayman Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.55 to $1.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":73135,"source":{"system":"sec-edgar","filing":"0001213900-26-075144","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026075144/ownership.xml","form_type":"4"}},{"id":718356,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-07-02T23:02:11.000Z","date":"2026-07-02","kind":"purchase","planned":false,"acquired":true,"shares":1460,"price":1.55,"value":2263.0,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.55 to $1.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":724395,"source":{"system":"sec-edgar","filing":"0001213900-26-075144","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026075144/ownership.xml","form_type":"4"}},{"id":718355,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-07-02T23:02:11.000Z","date":"2026-07-01","kind":"purchase","planned":false,"acquired":true,"shares":398,"price":1.55,"value":616.9,"ownership":{"direct":false,"nature":"By Vivo Opportunity Cayman Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.51 to $1.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":72988,"source":{"system":"sec-edgar","filing":"0001213900-26-075144","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026075144/ownership.xml","form_type":"4"}},{"id":718354,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-07-02T23:02:11.000Z","date":"2026-07-01","kind":"purchase","planned":false,"acquired":true,"shares":3946,"price":1.55,"value":6116.3,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.51 to $1.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":722935,"source":{"system":"sec-edgar","filing":"0001213900-26-075144","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026075144/ownership.xml","form_type":"4"}},{"id":718353,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-07-02T23:02:11.000Z","date":"2026-06-30","kind":"purchase","planned":false,"acquired":true,"shares":55,"price":1.54,"value":84.7,"ownership":{"direct":false,"nature":"By Vivo Opportunity Cayman Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.52 to $1.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":72590,"source":{"system":"sec-edgar","filing":"0001213900-26-075144","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026075144/ownership.xml","form_type":"4"}},{"id":718352,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-07-02T23:02:11.000Z","date":"2026-06-30","kind":"purchase","planned":false,"acquired":true,"shares":545,"price":1.54,"value":839.3,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.52 to $1.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":718989,"source":{"system":"sec-edgar","filing":"0001213900-26-075144","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026075144/ownership.xml","form_type":"4"}},{"id":743340,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-11T01:14:46.000Z","date":"2026-06-08","kind":"purchase","planned":false,"acquired":true,"shares":2982,"price":1.52,"value":4532.64,"ownership":{"direct":false,"nature":"By Vivo Opportunity Cayman Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.48 to $1.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (11) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":72535,"source":{"system":"sec-edgar","filing":"0001213900-26-067505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026067505/ownership.xml","form_type":"4"}},{"id":743339,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-11T01:14:46.000Z","date":"2026-06-08","kind":"purchase","planned":false,"acquired":true,"shares":29518,"price":1.52,"value":44867.36,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.48 to $1.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (11) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":718444,"source":{"system":"sec-edgar","filing":"0001213900-26-067505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026067505/ownership.xml","form_type":"4"}},{"id":743338,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-11T01:14:46.000Z","date":"2026-06-05","kind":"purchase","planned":false,"acquired":true,"shares":5045,"price":1.57,"value":7920.65,"ownership":{"direct":false,"nature":"By Vivo Opportunity Cayman Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.53 to $1.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (10) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":69553,"source":{"system":"sec-edgar","filing":"0001213900-26-067505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026067505/ownership.xml","form_type":"4"}},{"id":743337,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-11T01:14:46.000Z","date":"2026-06-05","kind":"purchase","planned":false,"acquired":true,"shares":49966,"price":1.57,"value":78446.62,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.53 to $1.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (10) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":688926,"source":{"system":"sec-edgar","filing":"0001213900-26-067505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026067505/ownership.xml","form_type":"4"}},{"id":743336,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-11T01:14:46.000Z","date":"2026-06-04","kind":"purchase","planned":false,"acquired":true,"shares":618,"price":1.57,"value":970.26,"ownership":{"direct":false,"nature":"By Vivo Opportunity Cayman Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.55 to $1.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (9) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":64508,"source":{"system":"sec-edgar","filing":"0001213900-26-067505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026067505/ownership.xml","form_type":"4"}},{"id":743335,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-11T01:14:46.000Z","date":"2026-06-04","kind":"purchase","planned":false,"acquired":true,"shares":6125,"price":1.57,"value":9616.25,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.55 to $1.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (9) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":638960,"source":{"system":"sec-edgar","filing":"0001213900-26-067505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026067505/ownership.xml","form_type":"4"}},{"id":743334,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-11T01:14:46.000Z","date":"2026-06-03","kind":"purchase","planned":false,"acquired":true,"shares":714,"price":1.55,"value":1106.7,"ownership":{"direct":false,"nature":"By Vivo Opportunity Cayman Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.50 to $1.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (8) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":63890,"source":{"system":"sec-edgar","filing":"0001213900-26-067505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026067505/ownership.xml","form_type":"4"}},{"id":743333,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-11T01:14:46.000Z","date":"2026-06-03","kind":"purchase","planned":false,"acquired":true,"shares":7069,"price":1.55,"value":10956.95,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.50 to $1.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (8) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":632835,"source":{"system":"sec-edgar","filing":"0001213900-26-067505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026067505/ownership.xml","form_type":"4"}},{"id":743332,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-11T01:14:46.000Z","date":"2026-06-02","kind":"purchase","planned":false,"acquired":true,"shares":2095,"price":1.52,"value":3184.4,"ownership":{"direct":false,"nature":"By Vivo Opportunity Cayman Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.49 to $1.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (7) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":63176,"source":{"system":"sec-edgar","filing":"0001213900-26-067505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026067505/ownership.xml","form_type":"4"}},{"id":743331,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-11T01:14:46.000Z","date":"2026-06-02","kind":"purchase","planned":false,"acquired":true,"shares":20753,"price":1.52,"value":31544.56,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.49 to $1.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (7) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":625766,"source":{"system":"sec-edgar","filing":"0001213900-26-067505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026067505/ownership.xml","form_type":"4"}},{"id":743330,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-11T01:14:46.000Z","date":"2026-06-01","kind":"purchase","planned":false,"acquired":true,"shares":1498,"price":1.55,"value":2321.9,"ownership":{"direct":false,"nature":"By Vivo Opportunity Cayman Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.49 to $1.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":61081,"source":{"system":"sec-edgar","filing":"0001213900-26-067505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026067505/ownership.xml","form_type":"4"}},{"id":743329,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-11T01:14:46.000Z","date":"2026-06-01","kind":"purchase","planned":false,"acquired":true,"shares":14838,"price":1.55,"value":22998.9,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.49 to $1.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":605013,"source":{"system":"sec-edgar","filing":"0001213900-26-067505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026067505/ownership.xml","form_type":"4"}},{"id":743328,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-11T01:14:46.000Z","date":"2026-05-29","kind":"purchase","planned":false,"acquired":true,"shares":1632,"price":1.57,"value":2562.24,"ownership":{"direct":false,"nature":"By Vivo Opportunity Cayman Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.55 to $1.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":59583,"source":{"system":"sec-edgar","filing":"0001213900-26-067505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026067505/ownership.xml","form_type":"4"}},{"id":743327,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-11T01:14:46.000Z","date":"2026-05-29","kind":"purchase","planned":false,"acquired":true,"shares":16164,"price":1.57,"value":25377.48,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.55 to $1.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":590175,"source":{"system":"sec-edgar","filing":"0001213900-26-067505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026067505/ownership.xml","form_type":"4"}},{"id":743326,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-11T01:14:46.000Z","date":"2026-05-21","kind":"purchase","planned":false,"acquired":true,"shares":3118,"price":1.69,"value":5269.42,"ownership":{"direct":false,"nature":"By Vivo Opportunity Cayman Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.53 to $1.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":57951,"source":{"system":"sec-edgar","filing":"0001213900-26-067505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026067505/ownership.xml","form_type":"4"}},{"id":743325,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-11T01:14:46.000Z","date":"2026-05-21","kind":"purchase","planned":false,"acquired":true,"shares":30882,"price":1.69,"value":52190.58,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.53 to $1.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":574011,"source":{"system":"sec-edgar","filing":"0001213900-26-067505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026067505/ownership.xml","form_type":"4"}},{"id":743324,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-11T01:14:46.000Z","date":"2026-05-20","kind":"purchase","planned":false,"acquired":true,"shares":5154,"price":1.56,"value":8040.24,"ownership":{"direct":false,"nature":"By Vivo Opportunity Cayman Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.42 to $1.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":54833,"source":{"system":"sec-edgar","filing":"0001213900-26-067505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026067505/ownership.xml","form_type":"4"}},{"id":743323,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-11T01:14:46.000Z","date":"2026-05-20","kind":"purchase","planned":false,"acquired":true,"shares":51056,"price":1.56,"value":79647.36,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.42 to $1.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":543129,"source":{"system":"sec-edgar","filing":"0001213900-26-067505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026067505/ownership.xml","form_type":"4"}},{"id":1188859,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-03-28T23:03:30.000Z","date":"2025-03-28","kind":"sale","planned":false,"acquired":false,"shares":333557,"price":70.6,"value":23549124.2,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $67.0 to $73.8, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":4458294,"source":{"system":"sec-edgar","filing":"0001013762-25-004322","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000101376225004322/ownership.xml","form_type":"4"}},{"id":1188858,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-03-28T23:03:30.000Z","date":"2025-03-27","kind":"sale","planned":false,"acquired":false,"shares":1100000,"price":67.8,"value":74580000.0,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $65 to $72.8, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":4791851,"source":{"system":"sec-edgar","filing":"0001013762-25-004322","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000101376225004322/ownership.xml","form_type":"4"}},{"id":1188857,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-03-28T23:03:30.000Z","date":"2025-03-26","kind":"sale","planned":false,"acquired":false,"shares":400000,"price":65.8,"value":26320000.0,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $64.3 to $70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":5891851,"source":{"system":"sec-edgar","filing":"0001013762-25-004322","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000101376225004322/ownership.xml","form_type":"4"}},{"id":1419953,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-29T23:36:55.000Z","date":"2024-08-29","kind":"sale","planned":false,"acquired":false,"shares":100000,"price":47.22,"value":4722000.0,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $46.47 to $47.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":6291851,"source":{"system":"sec-edgar","filing":"0001213900-24-074051","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390024074051/ownership.xml","form_type":"4"}},{"id":1419952,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-29T23:36:55.000Z","date":"2024-08-28","kind":"sale","planned":false,"acquired":false,"shares":425000,"price":47.35,"value":20123750.0,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $46.79 to $48.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":6391851,"source":{"system":"sec-edgar","filing":"0001213900-24-074051","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390024074051/ownership.xml","form_type":"4"}},{"id":1419951,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-29T23:36:55.000Z","date":"2024-08-27","kind":"sale","planned":false,"acquired":false,"shares":500000,"price":48.73,"value":24365000.0,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $47.00 to $51.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":6816851,"source":{"system":"sec-edgar","filing":"0001213900-24-074051","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390024074051/ownership.xml","form_type":"4"}},{"id":1532032,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-05-01T17:10:51.000Z","date":"2024-04-30","kind":"sale","planned":false,"acquired":false,"shares":351242,"price":45.13,"value":15851551.46,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $45.00 to $47.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":7316851,"source":{"system":"sec-edgar","filing":"0001213900-24-038343","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390024038343/ownership.xml","form_type":"4"}},{"id":1532031,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-05-01T17:10:51.000Z","date":"2024-04-29","kind":"sale","planned":false,"acquired":false,"shares":750000,"price":47.8,"value":35850000.0,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $45.00 to $53.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":7668093,"source":{"system":"sec-edgar","filing":"0001213900-24-038343","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390024038343/ownership.xml","form_type":"4"}},{"id":1549809,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":3,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":4,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":5,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:47:21.000Z","date":"2024-04-03","kind":"sale","planned":true,"acquired":false,"shares":4149,"price":6.2,"value":25723.8,"ownership":{"direct":false,"nature":"By: Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $5.97 to $6.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (7) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":268573,"source":{"system":"sec-edgar","filing":"0001213900-24-030020","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390024030020/ownership.xml","form_type":"4"}},{"id":1549808,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":3,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":4,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":5,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:47:21.000Z","date":"2024-04-03","kind":"sale","planned":true,"acquired":false,"shares":30047,"price":6.2,"value":186291.4,"ownership":{"direct":false,"nature":"By: Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $5.97 to $6.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (7) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":1945015,"source":{"system":"sec-edgar","filing":"0001213900-24-030020","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390024030020/ownership.xml","form_type":"4"}},{"id":1549807,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":3,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":4,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":5,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:47:21.000Z","date":"2024-04-03","kind":"sale","planned":true,"acquired":false,"shares":103870,"price":6.2,"value":643994.0,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $5.97 to $6.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (7) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the General Partner of Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":4023741,"source":{"system":"sec-edgar","filing":"0001213900-24-030020","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390024030020/ownership.xml","form_type":"4"}},{"id":1549806,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":3,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":4,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":5,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:47:21.000Z","date":"2024-04-02","kind":"sale","planned":true,"acquired":false,"shares":3050,"price":6.65,"value":20282.5,"ownership":{"direct":false,"nature":"By: Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $6.50 to $6.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":272722,"source":{"system":"sec-edgar","filing":"0001213900-24-030020","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390024030020/ownership.xml","form_type":"4"}},{"id":1549805,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":3,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":4,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":5,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:47:21.000Z","date":"2024-04-02","kind":"sale","planned":true,"acquired":false,"shares":22084,"price":6.65,"value":146858.6,"ownership":{"direct":false,"nature":"By: Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $6.50 to $6.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":1975062,"source":{"system":"sec-edgar","filing":"0001213900-24-030020","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390024030020/ownership.xml","form_type":"4"}},{"id":1549804,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":3,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":4,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":5,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:47:21.000Z","date":"2024-04-02","kind":"sale","planned":true,"acquired":false,"shares":76346,"price":6.65,"value":507700.9,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $6.50 to $6.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the General Partner of Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":4127611,"source":{"system":"sec-edgar","filing":"0001213900-24-030020","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390024030020/ownership.xml","form_type":"4"}},{"id":1549803,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":3,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":4,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":5,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:47:21.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":5451,"price":6.99,"value":38102.49,"ownership":{"direct":false,"nature":"By: Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $6.71 to $7.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":275772,"source":{"system":"sec-edgar","filing":"0001213900-24-030020","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390024030020/ownership.xml","form_type":"4"}},{"id":1549802,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":3,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":4,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":5,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:47:21.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":39411,"price":6.99,"value":275482.89,"ownership":{"direct":false,"nature":"By: Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $6.71 to $7.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":1997146,"source":{"system":"sec-edgar","filing":"0001213900-24-030020","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390024030020/ownership.xml","form_type":"4"}},{"id":1549801,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":3,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":4,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":5,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:47:21.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":136255,"price":6.99,"value":952422.45,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $6.71 to $7.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the General Partner of Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":4203957,"source":{"system":"sec-edgar","filing":"0001213900-24-030020","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390024030020/ownership.xml","form_type":"4"}},{"id":1731318,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":5,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":6,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":7,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-22T23:51:43.000Z","date":"2023-11-21","kind":"sale","planned":false,"acquired":false,"shares":1457,"price":0.9,"value":1311.3,"ownership":{"direct":false,"nature":"By: Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.90 to $0.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the General Partner of Vivo Opportunity Holdings, L.P. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":111662,"source":{"system":"sec-edgar","filing":"0001213900-23-089692","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390023089692/ownership.xml","form_type":"4"}},{"id":1731317,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":5,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":6,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":7,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-22T23:51:43.000Z","date":"2023-11-21","kind":"sale","planned":false,"acquired":false,"shares":236,"price":0.9,"value":212.4,"ownership":{"direct":false,"nature":"By: Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.90 to $0.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by Vivo Capital Surplus Fund VIII, L.P. Capital VIII, LLC is the General Partner of Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":269587,"source":{"system":"sec-edgar","filing":"0001213900-23-089692","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390023089692/ownership.xml","form_type":"4"}},{"id":1731316,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":5,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":6,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":7,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-22T23:51:43.000Z","date":"2023-11-21","kind":"sale","planned":false,"acquired":false,"shares":1707,"price":0.9,"value":1536.3,"ownership":{"direct":false,"nature":"By: Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.90 to $0.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":1952302,"source":{"system":"sec-edgar","filing":"0001213900-23-089692","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390023089692/ownership.xml","form_type":"4"}},{"id":1734699,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":5,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":6,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":7,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-21T02:09:11.000Z","date":"2023-11-20","kind":"sale","planned":false,"acquired":false,"shares":23443,"price":0.92,"value":21567.56,"ownership":{"direct":false,"nature":"By: Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.92 to $0.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the General Partner of Vivo Opportunity Holdings, L.P. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":113119,"source":{"system":"sec-edgar","filing":"0001213900-23-088909","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390023088909/ownership.xml","form_type":"4"}},{"id":1734698,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":5,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":6,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":7,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-21T02:09:11.000Z","date":"2023-11-20","kind":"sale","planned":false,"acquired":false,"shares":3792,"price":0.92,"value":3488.64,"ownership":{"direct":false,"nature":"By: Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.92 to $0.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by Vivo Capital Surplus Fund VIII, L.P. Capital VIII, LLC is the General Partner of Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":269823,"source":{"system":"sec-edgar","filing":"0001213900-23-088909","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390023088909/ownership.xml","form_type":"4"}},{"id":1734697,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":5,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":6,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":7,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-21T02:09:11.000Z","date":"2023-11-20","kind":"sale","planned":false,"acquired":false,"shares":27465,"price":0.92,"value":25267.8,"ownership":{"direct":false,"nature":"Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.92 to $0.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":1954009,"source":{"system":"sec-edgar","filing":"0001213900-23-088909","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390023088909/ownership.xml","form_type":"4"}},{"id":1734696,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":5,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":6,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":7,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-21T02:09:11.000Z","date":"2023-11-17","kind":"sale","planned":false,"acquired":false,"shares":7009,"price":0.93,"value":6518.37,"ownership":{"direct":false,"nature":"By: Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.93 to $0.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the General Partner of Vivo Opportunity Holdings, L.P. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":136562,"source":{"system":"sec-edgar","filing":"0001213900-23-088909","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390023088909/ownership.xml","form_type":"4"}},{"id":1734695,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":5,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":6,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":7,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-21T02:09:11.000Z","date":"2023-11-17","kind":"sale","planned":false,"acquired":false,"shares":1134,"price":0.93,"value":1054.62,"ownership":{"direct":false,"nature":"By: Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.93 to $0.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by Vivo Capital Surplus Fund VIII, L.P. Capital VIII, LLC is the General Partner of Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":273615,"source":{"system":"sec-edgar","filing":"0001213900-23-088909","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390023088909/ownership.xml","form_type":"4"}},{"id":1734694,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":5,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":6,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":7,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Comon Stock","published_at":"2023-11-21T02:09:11.000Z","date":"2023-11-17","kind":"sale","planned":false,"acquired":false,"shares":8211,"price":0.93,"value":7636.23,"ownership":{"direct":false,"nature":"By: Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.93 to $0.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":1981474,"source":{"system":"sec-edgar","filing":"0001213900-23-088909","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390023088909/ownership.xml","form_type":"4"}},{"id":1734693,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":5,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":6,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":7,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-21T02:09:11.000Z","date":"2023-11-16","kind":"sale","planned":false,"acquired":false,"shares":6429,"price":0.96,"value":6171.84,"ownership":{"direct":false,"nature":"By: Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.95 to $0.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the General Partner of Vivo Opportunity Holdings, L.P. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":143571,"source":{"system":"sec-edgar","filing":"0001213900-23-088909","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390023088909/ownership.xml","form_type":"4"}},{"id":1734692,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":5,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":6,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":7,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-21T02:09:11.000Z","date":"2023-11-16","kind":"sale","planned":false,"acquired":false,"shares":1040,"price":0.96,"value":998.4,"ownership":{"direct":false,"nature":"By: Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.95 to $0.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by Vivo Capital Surplus Fund VIII, L.P. Capital VIII, LLC is the General Partner of Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":274749,"source":{"system":"sec-edgar","filing":"0001213900-23-088909","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390023088909/ownership.xml","form_type":"4"}},{"id":1734691,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":5,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":6,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":7,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-21T02:09:11.000Z","date":"2023-11-16","kind":"sale","planned":false,"acquired":false,"shares":7531,"price":0.96,"value":7229.76,"ownership":{"direct":false,"nature":"By: Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.95 to $0.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":1989685,"source":{"system":"sec-edgar","filing":"0001213900-23-088909","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390023088909/ownership.xml","form_type":"4"}},{"id":1765363,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Tranche B Warrants (right to buy)","published_at":"2023-10-04T20:30:15.000Z","date":"2023-10-02","kind":"other","planned":false,"acquired":false,"shares":5215000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Tranche B Warrants are immediately exercisable and expire upon the earlier of (i) November 8, 2026 or (ii) 30 days following receipt of Food and Drug Administration's marketing approval of Diazoxide Choline Extended-Release tablets (DCCR) for the treatment of Prader-Willi syndrome (PWS)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Tranche B Warrants are immediately exercisable and expire upon the earlier of (i) November 8, 2026 or (ii) 30 days following receipt of Food and Drug Administration's marketing approval of Diazoxide Choline Extended-Release tablets (DCCR) for the treatment of Prader-Willi syndrome (PWS)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"exercise_price":2.5,"underlying":"Common Stock","underlying_shares":5215000},"source":{"system":"sec-edgar","filing":"0001013762-23-001637","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000101376223001637/ownership.xml","form_type":"4"}},{"id":1765362,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-10-04T20:30:15.000Z","date":"2023-10-02","kind":"other","planned":false,"acquired":true,"shares":5215000,"price":2.5,"value":13037500.0,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":8418093,"source":{"system":"sec-edgar","filing":"0001013762-23-001637","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000101376223001637/ownership.xml","form_type":"4"}},{"id":1772151,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Tranche A Warrants (right to buy)","published_at":"2023-09-28T21:00:26.000Z","date":"2023-09-26","kind":"other","planned":false,"acquired":false,"shares":3203093,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Tranche A Warrants are immediately exercisable and expire upon the earlier of (i) November 8, 2026 or (ii) 30 days of announcement of positive top-line data from the randomized withdrawal period of the Issuer's Study C602, an open-label extension study pertaining to Diazoxide Choline Extended-Release tablets (DCCR) for the treatment of Prader-Willi syndrome (PWS)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Tranche A Warrants are immediately exercisable and expire upon the earlier of (i) November 8, 2026 or (ii) 30 days of announcement of positive top-line data from the randomized withdrawal period of the Issuer's Study C602, an open-label extension study pertaining to Diazoxide Choline Extended-Release tablets (DCCR) for the treatment of Prader-Willi syndrome (PWS)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"exercise_price":1.75,"underlying":"Common Stock","underlying_shares":3203093},"source":{"system":"sec-edgar","filing":"0001213900-23-080555","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390023080555/ownership.xml","form_type":"4"}},{"id":1772150,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-28T21:00:26.000Z","date":"2023-09-26","kind":"other","planned":false,"acquired":true,"shares":3203093,"price":1.75,"value":5605412.75,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":3203093,"source":{"system":"sec-edgar","filing":"0001213900-23-080555","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390023080555/ownership.xml","form_type":"4"}},{"id":1810990,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":3,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":4,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (Right to Buy)","published_at":"2023-08-10T13:03:21.000Z","date":"2023-08-09","kind":"purchase","planned":false,"acquired":true,"shares":3157894,"price":0.125,"value":394736.75,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Purchase was made pursuant to that certain Securities Purchase Agreement dated as of August 7, 2023, by and among the Issuer and the purchasers named therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These warrants expire at 5:00 p.m. on the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an Acquisition of the Issuer, as defined in the Form of Warrant, attached as Exhibit 4.1 to the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 7, 2023, provided that the holder will be prohibited from exercising these warrants if, after giving effect to such exercise, the holder (together with such holder's affiliates and any other persons acting as a group together) would beneficially own in excess of 9.99% of the shares of common stock of the Issuer outstanding immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These warrants expire at 5:00 p.m. on the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an Acquisition of the Issuer, as defined in the Form of Warrant, attached as Exhibit 4.1 to the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 7, 2023, provided that the holder will be prohibited from exercising these warrants if, after giving effect to such exercise, the holder (together with such holder's affiliates and any other persons acting as a group together) would beneficially own in excess of 9.99% of the shares of common stock of the Issuer outstanding immediately after giving effect to such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held directly by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. As the managing members of Vivo Opportunity, LLC, Gaurav Aggarwal, Hongbo Lu, Kevin Dai, Frank Kung and Michael Chang share voting and dispositive power over the securities held by Vivo Opportunity Fund Holdings, L.P., but each disclaims beneficial ownership of such securities except to the extent of their individual pecuniary interest therein."}],"balance_after":3157894,"derivative":{"exercise_price":2.47,"exercise_date":"2023-08-09","underlying":"Common Stock","underlying_shares":3157894},"source":{"system":"sec-edgar","filing":"0001213900-23-065297","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000121390023065297/ownership.xml","form_type":"4"}},{"id":1810989,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":3,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":4,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-10T13:03:21.000Z","date":"2023-08-09","kind":"purchase","planned":false,"acquired":true,"shares":3157894,"price":1.9,"value":5999998.6,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Purchase was made pursuant to that certain Securities Purchase Agreement dated as of August 7, 2023, by and among the Issuer and the purchasers named therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held directly by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. As the managing members of Vivo Opportunity, LLC, Gaurav Aggarwal, Hongbo Lu, Kevin Dai, Frank Kung and Michael Chang share voting and dispositive power over the securities held by Vivo Opportunity Fund Holdings, L.P., but each disclaims beneficial ownership of such securities except to the extent of their individual pecuniary interest therein."}],"balance_after":3157894,"source":{"system":"sec-edgar","filing":"0001213900-23-065297","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000121390023065297/ownership.xml","form_type":"4"}},{"id":2076833,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":3,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":4,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":5,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:48:58.000Z","date":"2022-12-23","kind":"purchase","acquired":true,"shares":758620,"price":7.25,"value":5499995.0,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Gaurav Aggarwal, Hongbo Lu, Kevin Dai, Frank Kung and Michael Chang are managing members of Vivo Opportunity, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund Holdings, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his or her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":4340212,"source":{"system":"sec-edgar","filing":"0001213900-22-082664","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390022082664/ownership.xml","form_type":"4"}},{"id":2163179,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":3,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":4,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":5,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-09-09T00:00:48.000Z","date":"2022-09-07","kind":"purchase","acquired":true,"shares":600000,"price":3.6,"value":2160000.0,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Gaurav Aggarwal, Hongbo Lu, Kevin Dai, Frank Kung and Michael Chang are managing members of Vivo Opportunity, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund Holdings, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his or her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":3581592,"source":{"system":"sec-edgar","filing":"0001213900-22-054888","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390022054888/ownership.xml","form_type":"4"}},{"id":2184338,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":3,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":4,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":5,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-funded Warrants (right to buy)","published_at":"2022-08-17T00:44:38.000Z","date":"2022-08-16","kind":"purchase","acquired":true,"shares":1500000,"price":2.4199,"value":3629850.0,"ownership":{"direct":false,"nature":"By: Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The reporting person acquired 1,500,000 shares of Common Stock at $2.42 per share and 1,500,000 pre-funded warrants at $2.41990 per warrant in an underwritten offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the reporting person and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 4.99% of the outstanding shares of Common Stock of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the reporting person and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 4.99% of the outstanding shares of Common Stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Gaurav Aggarwal, Hongbo Lu, Kevin Dai, Frank Kung and Michael Chang are managing members of Vivo Opportunity, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund Holdings, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his or her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":1500000,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":1500000},"source":{"system":"sec-edgar","filing":"0001213900-22-048763","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390022048763/ownership.xml","form_type":"4"}},{"id":2184337,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":3,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":4,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":5,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-17T00:44:38.000Z","date":"2022-08-16","kind":"purchase","acquired":true,"shares":1500000,"price":2.42,"value":3630000.0,"ownership":{"direct":false,"nature":"By: Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The reporting person acquired 1,500,000 shares of Common Stock at $2.42 per share and 1,500,000 pre-funded warrants at $2.41990 per warrant in an underwritten offering."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reporting person acquired 1,500,000 shares of Common Stock at $2.42 per share and 1,500,000 pre-funded warrants at $2.41990 per warrant in an underwritten offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Gaurav Aggarwal, Hongbo Lu, Kevin Dai, Frank Kung and Michael Chang are managing members of Vivo Opportunity, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund Holdings, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his or her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":2981592,"source":{"system":"sec-edgar","filing":"0001213900-22-048763","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390022048763/ownership.xml","form_type":"4"}},{"id":2184336,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":3,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":4,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":5,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-17T00:44:38.000Z","date":"2022-08-15","kind":"purchase","acquired":true,"shares":1218,"price":2.99,"value":3641.82,"ownership":{"direct":false,"nature":"By: Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $2.96 to $3.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Gaurav Aggarwal, Hongbo Lu, Kevin Dai, Frank Kung and Michael Chang are managing members of Vivo Opportunity, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund Holdings, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his or her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":1481592,"source":{"system":"sec-edgar","filing":"0001213900-22-048763","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390022048763/ownership.xml","form_type":"4"}},{"id":2184335,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":3,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":4,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":5,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-17T00:44:38.000Z","date":"2022-08-12","kind":"purchase","acquired":true,"shares":1123021,"price":2.98,"value":3346602.58,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $2.83 to $3.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Gaurav Aggarwal, Hongbo Lu, Kevin Dai, Frank Kung and Michael Chang are managing members of Vivo Opportunity, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund Holdings, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his or her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":1480374,"source":{"system":"sec-edgar","filing":"0001213900-22-048763","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390022048763/ownership.xml","form_type":"4"}},{"id":2217391,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrants","published_at":"2022-07-01T16:59:45.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":75749,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By: Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P."},"footnotes":[{"field":"timeliness","element":"transactionTimeliness","label":"F5","text":"Pursuant to the terms of the Merger Agreement, the Issuer's outstanding Series A Warrants (the \"Series A Warrants\") were treated in accordance with their respective terms such that, at the effective time of the Merger, the outstanding Series A Warrants were cancelled and thereafter represent only the right to receive an amount in cash, without interest, equal to the Black Scholes Value (as defined in the Series A Warrants), which as calculated under the terms of the Series A Warrants equaled $45.98 per share of common stock underlying such warrants."},{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated April 12, 2022, between GlaxoSmithKline plc (\"GSK\"), Orikum Acquisition Inc. (\"Merger Sub\") and the Issuer (the \"Merger Agreement\"), Merger Sub merged with and into the Issuer on July 1, 2022, with the Issuer surviving as a wholly-owned subsidiary of GSK (the \"Merger\"). At the effective time of the Merger, each outstanding share of common stock of the Issuer automatically and without any required action on the part of the Reporting Person, was converted into the right to receive $55.00 in cash, without interest."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Vivo Capital IX, LLC (\"Vivo Capital IX LLC\") is the general partner of Vivo Capital Fund IX, L.P., the record holder of the securities. Vivo Capital IX LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Ventures VII, LLC (\"Vivo Ventures LLC\") is the general partner of each of Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P. (\"Vivo Fund VII\"), the record holder of the securities. Vivo Ventures LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"exercise_price":13.2,"exercise_date":"2019-11-13","expiration_date":"2024-11-13","underlying":"Common Stock","underlying_shares":75749},"source":{"system":"sec-edgar","filing":"0001213900-22-036724","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022036724/ownership.xml","form_type":"4"}},{"id":2217390,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrants","published_at":"2022-07-01T16:59:45.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":1455384,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By: Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"timeliness","element":"transactionTimeliness","label":"F5","text":"Pursuant to the terms of the Merger Agreement, the Issuer's outstanding Series A Warrants (the \"Series A Warrants\") were treated in accordance with their respective terms such that, at the effective time of the Merger, the outstanding Series A Warrants were cancelled and thereafter represent only the right to receive an amount in cash, without interest, equal to the Black Scholes Value (as defined in the Series A Warrants), which as calculated under the terms of the Series A Warrants equaled $45.98 per share of common stock underlying such warrants."},{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated April 12, 2022, between GlaxoSmithKline plc (\"GSK\"), Orikum Acquisition Inc. (\"Merger Sub\") and the Issuer (the \"Merger Agreement\"), Merger Sub merged with and into the Issuer on July 1, 2022, with the Issuer surviving as a wholly-owned subsidiary of GSK (the \"Merger\"). At the effective time of the Merger, each outstanding share of common stock of the Issuer automatically and without any required action on the part of the Reporting Person, was converted into the right to receive $55.00 in cash, without interest."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Vivo Capital IX, LLC (\"Vivo Capital IX LLC\") is the general partner of Vivo Capital Fund IX, L.P., the record holder of the securities. Vivo Capital IX LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Vivo Opportunity, LLC (\"Vivo Opportunity LLC\") is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"exercise_price":13.2,"exercise_date":"2019-11-13","expiration_date":"2024-11-13","underlying":"Common Stock","underlying_shares":1455384},"source":{"system":"sec-edgar","filing":"0001213900-22-036724","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022036724/ownership.xml","form_type":"4"}},{"id":2217389,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrants","published_at":"2022-07-01T16:59:45.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":324740,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By: Vivo Capital Fund IX, L.P."},"footnotes":[{"field":"timeliness","element":"transactionTimeliness","label":"F5","text":"Pursuant to the terms of the Merger Agreement, the Issuer's outstanding Series A Warrants (the \"Series A Warrants\") were treated in accordance with their respective terms such that, at the effective time of the Merger, the outstanding Series A Warrants were cancelled and thereafter represent only the right to receive an amount in cash, without interest, equal to the Black Scholes Value (as defined in the Series A Warrants), which as calculated under the terms of the Series A Warrants equaled $45.98 per share of common stock underlying such warrants."},{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated April 12, 2022, between GlaxoSmithKline plc (\"GSK\"), Orikum Acquisition Inc. (\"Merger Sub\") and the Issuer (the \"Merger Agreement\"), Merger Sub merged with and into the Issuer on July 1, 2022, with the Issuer surviving as a wholly-owned subsidiary of GSK (the \"Merger\"). At the effective time of the Merger, each outstanding share of common stock of the Issuer automatically and without any required action on the part of the Reporting Person, was converted into the right to receive $55.00 in cash, without interest."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Vivo Capital IX, LLC (\"Vivo Capital IX LLC\") is the general partner of Vivo Capital Fund IX, L.P., the record holder of the securities. Vivo Capital IX LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Capital IX, LLC (\"Vivo Capital IX LLC\") is the general partner of Vivo Capital Fund IX, L.P., the record holder of the securities. Vivo Capital IX LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"exercise_price":13.2,"exercise_date":"2019-11-13","expiration_date":"2024-11-13","underlying":"Common Stock","underlying_shares":324740},"source":{"system":"sec-edgar","filing":"0001213900-22-036724","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022036724/ownership.xml","form_type":"4"}},{"id":2217388,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-07-01T16:59:45.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":431947,"price":55,"value":23757085.0,"ownership":{"direct":false,"nature":"By: Vivo Capital Fund IX, L.P."},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated April 12, 2022, between GlaxoSmithKline plc (\"GSK\"), Orikum Acquisition Inc. (\"Merger Sub\") and the Issuer (the \"Merger Agreement\"), Merger Sub merged with and into the Issuer on July 1, 2022, with the Issuer surviving as a wholly-owned subsidiary of GSK (the \"Merger\"). At the effective time of the Merger, each outstanding share of common stock of the Issuer automatically and without any required action on the part of the Reporting Person, was converted into the right to receive $55.00 in cash, without interest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Capital IX, LLC (\"Vivo Capital IX LLC\") is the general partner of Vivo Capital Fund IX, L.P., the record holder of the securities. Vivo Capital IX LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001213900-22-036724","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022036724/ownership.xml","form_type":"4"}},{"id":2217387,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-07-01T16:59:45.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":2735853,"price":55,"value":150471915.0,"ownership":{"direct":false,"nature":"By: Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated April 12, 2022, between GlaxoSmithKline plc (\"GSK\"), Orikum Acquisition Inc. (\"Merger Sub\") and the Issuer (the \"Merger Agreement\"), Merger Sub merged with and into the Issuer on July 1, 2022, with the Issuer surviving as a wholly-owned subsidiary of GSK (the \"Merger\"). At the effective time of the Merger, each outstanding share of common stock of the Issuer automatically and without any required action on the part of the Reporting Person, was converted into the right to receive $55.00 in cash, without interest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Vivo Opportunity, LLC (\"Vivo Opportunity LLC\") is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001213900-22-036724","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022036724/ownership.xml","form_type":"4"}},{"id":2217386,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-07-01T16:59:45.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":161712,"price":55,"value":8894160.0,"ownership":{"direct":false,"nature":"By: Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P."},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated April 12, 2022, between GlaxoSmithKline plc (\"GSK\"), Orikum Acquisition Inc. (\"Merger Sub\") and the Issuer (the \"Merger Agreement\"), Merger Sub merged with and into the Issuer on July 1, 2022, with the Issuer surviving as a wholly-owned subsidiary of GSK (the \"Merger\"). At the effective time of the Merger, each outstanding share of common stock of the Issuer automatically and without any required action on the part of the Reporting Person, was converted into the right to receive $55.00 in cash, without interest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Ventures VII, LLC (\"Vivo Ventures LLC\") is the general partner of each of Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P. (\"Vivo Fund VII\"), the record holder of the securities. Vivo Ventures LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001213900-22-036724","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022036724/ownership.xml","form_type":"4"}},{"id":2421164,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-31T21:30:36.000Z","date":"2022-01-31","kind":"purchase","acquired":true,"shares":800000,"price":27,"value":21600000.0,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P., the record holder of the securities. Gaurav Aggarwal, Hongbo Lu, Kevin Dai, Frank Kung and Michael Chang are managing members of Vivo Opportunity, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his or her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":2735853,"source":{"system":"sec-edgar","filing":"0001213900-22-004647","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022004647/ownership.xml","form_type":"4"}},{"id":2422603,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrant (Right to Purchase )","published_at":"2022-01-28T20:12:59.000Z","date":"2022-01-26","kind":"other","acquired":false,"shares":324740,"price":13.2,"value":4286568.0,"ownership":{"direct":false,"nature":"By: Vivo Capital Fund IX, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"shares","element":"transactionShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B Warrants will expire on the 75th day anniversary of the Issuer's announcement of the top-line data results from MOMENTUM. The Issuer announced such data on January 25, 2022."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P., the record holder of the securities. Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Mahendra Shah, Jack Nielsen and Michael Chang are managing members of Vivo Capital IX, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund IX, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his or her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"exercise_price":13.2,"exercise_date":"2020-01-22","underlying":"Common Stock","underlying_shares":107164},"source":{"system":"sec-edgar","filing":"0001213900-22-004318","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022004318/ownership.xml","form_type":"4"}},{"id":2422602,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrant (Right to Purchase )","published_at":"2022-01-28T20:12:59.000Z","date":"2022-01-26","kind":"other","acquired":false,"shares":1455384,"price":13.2,"value":19211068.8,"ownership":{"direct":false,"nature":"By: Vivo Opportunity Fund, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"shares","element":"transactionShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B Warrants will expire on the 75th day anniversary of the Issuer's announcement of the top-line data results from MOMENTUM. The Issuer announced such data on January 25, 2022."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P., the record holder of the securities. Gaurav Aggarwal, Hongbo Lu, Kevin Dai, Frank Kung and Michael Chang are managing members of Vivo Opportunity, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his or her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"exercise_price":13.2,"exercise_date":"2020-01-22","underlying":"Common Stock","underlying_shares":480277},"source":{"system":"sec-edgar","filing":"0001213900-22-004318","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022004318/ownership.xml","form_type":"4"}},{"id":2422601,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrant (Right to Purchase )","published_at":"2022-01-28T20:12:59.000Z","date":"2022-01-26","kind":"other","acquired":false,"shares":75749,"price":13.2,"value":999886.8,"ownership":{"direct":false,"nature":"By: Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"shares","element":"transactionShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B Warrants will expire on the 75th day anniversary of the Issuer's announcement of the top-line data results from MOMENTUM. The Issuer announced such data on January 25, 2022."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Vivo Ventures VII, LLC is the general partner of each of Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P. (\"Vivo Fund VII\"), the record holder of the securities. Frank Kung, Edgar Engleman and Shan Fu are managing members of Vivo Ventures VII, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Fund VII. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"exercise_price":13.2,"exercise_date":"2020-01-22","underlying":"Common Stock","underlying_shares":24996},"source":{"system":"sec-edgar","filing":"0001213900-22-004318","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022004318/ownership.xml","form_type":"4"}},{"id":2422600,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-28T20:12:59.000Z","date":"2022-01-26","kind":"other","acquired":true,"shares":107164,"price":13.2,"value":1414564.8,"ownership":{"direct":false,"nature":"By: Vivo Capital Fund IX, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P., the record holder of the securities. Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Mahendra Shah, Jack Nielsen and Michael Chang are managing members of Vivo Capital IX, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund IX, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his or her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":431947,"source":{"system":"sec-edgar","filing":"0001213900-22-004318","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022004318/ownership.xml","form_type":"4"}},{"id":2422599,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-28T20:12:59.000Z","date":"2022-01-26","kind":"other","acquired":true,"shares":480277,"price":13.2,"value":6339656.4,"ownership":{"direct":false,"nature":"By: Vivo Opportunity Fund, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P., the record holder of the securities. Gaurav Aggarwal, Hongbo Lu, Kevin Dai, Frank Kung and Michael Chang are managing members of Vivo Opportunity, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his or her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":1935853,"source":{"system":"sec-edgar","filing":"0001213900-22-004318","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022004318/ownership.xml","form_type":"4"}},{"id":2422598,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-28T20:12:59.000Z","date":"2022-01-26","kind":"other","acquired":true,"shares":24996,"price":13.2,"value":329947.2,"ownership":{"direct":false,"nature":"By: Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Vivo Ventures VII, LLC is the general partner of each of Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P. (\"Vivo Fund VII\"), the record holder of the securities. Frank Kung, Edgar Engleman and Shan Fu are managing members of Vivo Ventures VII, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Fund VII. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":161712,"source":{"system":"sec-edgar","filing":"0001213900-22-004318","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022004318/ownership.xml","form_type":"4"}},{"id":2872094,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"other","acquired":false,"shares":5655,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The shares subject to this warrant were fully vested prior to exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":0,"derivative":{"exercise_price":0.07,"expiration_date":"2028-07-26","underlying":"Common Stock","underlying_shares":5655},"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872093,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-2 Preferred Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":47718,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":47718},"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872092,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":43901,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":43901},"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872091,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":150802,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":150802},"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872090,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"other","acquired":false,"shares":40953,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The shares subject to this warrant were fully vested prior to exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":0,"derivative":{"exercise_price":0.07,"expiration_date":"2028-07-26","underlying":"Common Stock","underlying_shares":40953},"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872089,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-2 Preferred Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":345568,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":345568},"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872088,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":317922,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":317922},"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872087,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":1092080,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1092080},"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872086,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"other","acquired":false,"shares":17711,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo PANDA Fund, L.P."},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The shares subject to this warrant were fully vested prior to exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held of record by Vivo PANDA Fund, L.P. (\"Vivo LP\"). Vivo Panda, LLC (\"Vivo LLC\") is the sole general partner of Vivo LP. Mahendra G. Shah, Ph.D. is one of four voting members of Vivo LLC."}],"balance_after":0,"derivative":{"exercise_price":0.07,"expiration_date":"2028-07-26","underlying":"Common Stock","underlying_shares":17711},"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872085,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":472296,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo PANDA Fund, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held of record by Vivo PANDA Fund, L.P. (\"Vivo LP\"). Vivo Panda, LLC (\"Vivo LLC\") is the sole general partner of Vivo LP. Mahendra G. Shah, Ph.D. is one of four voting members of Vivo LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":472296},"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872084,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":944056,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo PANDA Fund, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of\nthe Issuer's initial public offering (the \"IPO\") and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of\nthe Issuer's initial public offering (the \"IPO\") and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of\nthe Issuer's initial public offering (the \"IPO\") and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held of record by Vivo PANDA Fund, L.P. (\"Vivo LP\"). Vivo Panda, LLC (\"Vivo LLC\") is the sole general partner of Vivo LP. Mahendra G. Shah, Ph.D. is one of four voting members of Vivo LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":944056},"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872083,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"purchase","acquired":true,"shares":150000,"price":20,"value":3000000.0,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held of record by Vivo Opportunity Fund, L.P. (VOF). Vivo Opportunity, LLC is the general partner of VOF and has four managing members."}],"balance_after":150000,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872082,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"purchase","acquired":true,"shares":24267,"price":20,"value":485340.0,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":275789,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872081,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"sale","acquired":false,"shares":20,"price":20,"value":400.0,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F10","text":"Upon closing of the Issuer's IPO, Vivo Capital Surplus Fund VIII, L.P. exercised a warrant to purchase 5,655 shares of the Issuer's Common Stock at an exercise price per share of $0.07. Vivo Capital Surplus Fund VIII, L.P. paid the exercise price on a cashless basis, resulting in the Issuer withholding 20 share subject to the warrant in order to pay the exercise price and issuing to Vivo Capital Surplus Fund VIII, L.P. the remaining 5,635 shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":251522,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872080,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"other","acquired":true,"shares":5655,"price":0.07,"value":395.85,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":251542,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872079,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":47718,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":245887,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}}],"next_cursor":"2021-02-09T20:37:46.000000Z,2872079"}